Limits...
Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus

AFMSCs and SKOV3 cells tumorigenicity analysis by macroscopic and HE staining observation.Fig 6–1 Macroscopic observation.(A) SKOV3 cells formatted tumors on the right side of the 6 nude mice.(B) No tumor were seen in the right side of the the 6 AFMSCs injection nude mice. Fig 6–2 Nude mice scapular subcutaneous tissues HE staining. (A) Saline injection site HE staining in AFMSCs injection group.(B) AFMSCs injection site HE staining in AFMSCs injection group.(C)Saline injection site HE staining in SKOV3 cells injection group.(D) SKOV3 cells injection site accumulated many inflammatory cells.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g006: AFMSCs and SKOV3 cells tumorigenicity analysis by macroscopic and HE staining observation.Fig 6–1 Macroscopic observation.(A) SKOV3 cells formatted tumors on the right side of the 6 nude mice.(B) No tumor were seen in the right side of the the 6 AFMSCs injection nude mice. Fig 6–2 Nude mice scapular subcutaneous tissues HE staining. (A) Saline injection site HE staining in AFMSCs injection group.(B) AFMSCs injection site HE staining in AFMSCs injection group.(C)Saline injection site HE staining in SKOV3 cells injection group.(D) SKOV3 cells injection site accumulated many inflammatory cells.

Mentions: Two days after the AFMSCs injection, the right side of the nude mice in the AF injection group showed soft skin rashes at the injection site and no skin rashes formatted on the left site.Three days later, the skin rashes on both sides of the 6 nude mice disappeared. 60 days after the injection, the mice were sacrificed, both the AFMSCs injection and saline injection scapular subcutaneous tissues were collected. By macroscopic observation (Fig 6-1)and HE staining(Fig 6-2), we found that no tumor generated. It meaned that the AFMSCs had no tumorigenicity and might be used in vivo safely.


Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

AFMSCs and SKOV3 cells tumorigenicity analysis by macroscopic and HE staining observation.Fig 6–1 Macroscopic observation.(A) SKOV3 cells formatted tumors on the right side of the 6 nude mice.(B) No tumor were seen in the right side of the the 6 AFMSCs injection nude mice. Fig 6–2 Nude mice scapular subcutaneous tissues HE staining. (A) Saline injection site HE staining in AFMSCs injection group.(B) AFMSCs injection site HE staining in AFMSCs injection group.(C)Saline injection site HE staining in SKOV3 cells injection group.(D) SKOV3 cells injection site accumulated many inflammatory cells.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g006: AFMSCs and SKOV3 cells tumorigenicity analysis by macroscopic and HE staining observation.Fig 6–1 Macroscopic observation.(A) SKOV3 cells formatted tumors on the right side of the 6 nude mice.(B) No tumor were seen in the right side of the the 6 AFMSCs injection nude mice. Fig 6–2 Nude mice scapular subcutaneous tissues HE staining. (A) Saline injection site HE staining in AFMSCs injection group.(B) AFMSCs injection site HE staining in AFMSCs injection group.(C)Saline injection site HE staining in SKOV3 cells injection group.(D) SKOV3 cells injection site accumulated many inflammatory cells.
Mentions: Two days after the AFMSCs injection, the right side of the nude mice in the AF injection group showed soft skin rashes at the injection site and no skin rashes formatted on the left site.Three days later, the skin rashes on both sides of the 6 nude mice disappeared. 60 days after the injection, the mice were sacrificed, both the AFMSCs injection and saline injection scapular subcutaneous tissues were collected. By macroscopic observation (Fig 6-1)and HE staining(Fig 6-2), we found that no tumor generated. It meaned that the AFMSCs had no tumorigenicity and might be used in vivo safely.

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus